Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Curr Atheroscler Rep
; 9(5): 359-66, 2007 Nov.
Article
en En
| MEDLINE
| ID: mdl-18001618
ABSTRACT
Rimonabant is a selective blocker of the CB(1) cannabinoid receptor that has been developed for treatment of abdominal obesity, dyslipidemia, and control of diabetes. Four randomized clinical trials have demonstrated that following 1 year of treatment, 20 mg/d of rimonabant is associated with greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is associated with favorable changes in serum high-density lipoprotein and triglycerides, as well as with an improvement in glycemic control among obese type 2 diabetic patients. Rimonabant appears to be well tolerated, with the most common side effects being nausea, anxiety, and depressive symptoms. Rimonabant is a novel agent that has the potential to be a useful adjunct to lifestyle and behavior modification in treatment of abdominal obesity, dyslipidemia, and dysglycemia.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Piperidinas
/
Pirazoles
/
Síndrome Metabólico
/
Endocannabinoides
/
Metabolismo de los Lípidos
/
Moduladores de Receptores de Cannabinoides
/
Obesidad
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Curr Atheroscler Rep
Asunto de la revista:
ANGIOLOGIA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Estados Unidos